Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YOLT-201 in ATTR-CM
NCT06082050Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Nov 2023
- Primary completion
- Jul 2025
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of YOLT-201 in transthyretin amyloidosis cardiomyopathy (ATTR-CM), sponsored by Zhejiang University. Primary endpoint: Adverse events at 1 year. Started Nov 2023; status: recruiting.
02
Drugs
YOLT-201
03
Conditions
transthyretin amyloidosis cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT06082050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06082050.